Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
unusual cranial manifestation of b cell precursor lymphoblastic lymphoma in 10 year old girl
Original title: “An unusual cranial manifestation of B-cell precursor lymphoblastic lymphoma in 10-year-old girl.”
spontaneous regression of b cell acute lymphoblastic leukemia with pax5 alterations at relapse a case report
Original title: “Spontaneous regression of B-cell acute lymphoblastic leukemia with PAX5 alterations at relapse: a case report.”
unusual presentation of philadelphia chromosome positive b cell acute lymphoblastic leukemia with isolated osteolytic lesions at diagnosis a case report
Original title: “An Unusual Presentation of Philadelphia Chromosome Positive B-Cell Acute Lymphoblastic Leukemia With Isolated Osteolytic Lesions at Diagnosis: A Case Report.”
tcf3 hlf positive b all integrated clinical and molecular characterization of 34 cases from a single center cohort
Original title: “TCF3::HLF-positive B-ALL: integrated clinical and molecular characterization of 34 cases from a single-center cohort.”
secondary philadelphia chromosome negative b cell acute lymphoblastic leukemia following prolonged lenalidomide maintenance in multiple myeloma
Original title: “Secondary Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia Following Prolonged Lenalidomide Maintenance in Multiple Myeloma.”
concurrent development of b cell lymphoblastic lymphoma and histiocytic sarcoma in a c57bl 6 laboratory mouse a case report
Original title: “Concurrent Development of B-Cell Lymphoblastic Lymphoma and Histiocytic Sarcoma in a C57BL/6 Laboratory Mouse: A Case Report.”
Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk. Reasonable remission rates were seen when inotuzumab ozogamicin was administered as a salvage therapy to patients with relapsed/refractory B-cell · acute lymphoblastic leukemia (B-ALL), with mean (SD) survival rates of 51.7% (8.1%) overall and 32.4% (8.0%) event-free, according to new research in · Blood Cancer Journal.1 These real-world data are helping to fill a data gap for such evidence currently left by limited studies in this disease and medication, which have been concentrated in clinical trial settings.2-4 Depth of response was clinically meaningful: MRD-negative status occurred in 71.4% of CR/CRi patients, enabling consolidation with ASCT or CAR T in 67.8% overall. Post-therapy hepatic SOS/veno-occlusive disease remained a major toxicity signal, with 9/10 cases after transplant and no clear correlation with cumulative dose or IO–transplant interval. European LeukemiaNet criteria. Of this group, 71.4% (n = 20) reached minimal residual disease–negative status, and 67.8% (n = 19) followed inotuzumab ozogamicin with allogeneic stem cell transplant (ASCT; n = 18) or chimeric antigen receptor (CAR) T-cell therapy (n = 1). Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data. Leuk Lymphoma. 2020;61(2):491-493. doi:10.1080/10428194.2019.1672057 · Molina O, Bataller A, Thampi N, et al. Near-haploidy and low-hypodiploidy in B-cell acute lymphoblastic leukemia: when less is too much. Cancers (Basel). 2021;14(1):32. doi:10.3390/cancers14010032 · Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults.
Original title: “Inotuzumab Ozogamicin Outcomes in ALL Validated Outside of Clinical Trials | AJMC”